Stabilized procedure for the determination of urokinase fibrinolytic potency.
A stabilized procedure for the determination of urokinase (UK) fibrinolytic potency is described in which method response is dependent on urokinase concentration and independent of normal variation in assay parameters. The method is a selective stability-indicating procedure for UK active enzyme. It is suitable for evaluation of both high molecular weight as well as low molecular weight urokinase fractions and is calibrated against the World Health Organization International Reference Preparation for UK code 66/46 using a biological six-point parallel line log-log dose-response approach where sample and standard are compared under essentially identical conditions. High method stability and sensitivity are achieved through the use of appropriate levels of purified human plasminogen and human plasma (source of fibrinogen) as primary and secondary substrates, respectively. Method precision versus house reference standard (%RSD less than or equal to 2%) is suitable for research and pharmaceutical purposes. The absolute UK potency reference plane established in the calibrated procedure is equivalent to that established by other investigators in the fibrinolytic field.
Sutherland
J W
JW
Analytical Research, Department 417, Abbott Laboratories, North Chicago, Illinois 60064.
Banick
D W
DW
Schmakel
C O
CO
D000818:Animals; D002417:Cattle; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008970:Molecular Weight; D010958:Plasminogen; D012015:Reference Standards; D015203:Reproducibility of Results; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood*
D010958:Plasminogen; D014568:Urokinase-Type Plasminogen Activator